Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UFT plus leucovorin versus capecitabine in elderly patients with advanced colorectal cancer
NL-OMON20018Phase 3Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) comparing UFT plus leucovorin with Capecitabine (2 arms). Primary endpoint: Progression-free survival. Started Jan 2008; status: active, not recruiting.
02
Drugs
tegafur + uracilfolinic acidcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON20018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20018.